Evidence map›Paper›PMID 36033360›Full record

ArticleContemporary clinical trials communications2022

Access to urologists for participation in research: An analysis of NCI's Community Oncology Research Program landscape survey.

Shellie D Ellis, Riha Vaidya, Joseph M Unger, Kelly Stratton, Jessie Gills, Peter Van Veldhuizen, Eileen Mederos, Emily V Dressler, Matthew F Hudson, Charles Kamen and 4 more

Abstract read
In one paragraph

Article in Contemporary clinical trials communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shellie D EllisUniversity of Kansas Cancer Center, University of Kansas Medical Center, USA.
Riha VaidyaSWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, USA.
Joseph M UngerSWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, USA.
Kelly StrattonStephenson Cancer Center, University of Oklahoma Health Sciences Center, USA.
Jessie GillsGulf South NCORP, Louisiana State University Health Sciences Center, USA.
Peter Van VeldhuizenUniversity of Rochester Medical Center, USA.
Eileen MederosGulf South NCORP, Louisiana State University Health Sciences Center, USA.
Emily V DresslerWake Forest School of Medicine, Department of Biostatistics and Data Science, Winston-Salem, NC, USA.
Matthew F HudsonPrisma Health, Greenville, SC, USA.
Charles KamenUniversity of Rochester Medical Center, USA.
Heather B NeumanUniversity of Wisconsin School of Medicine and Public Health, Madison, USA.
Anne E KazakNemours Children's Health, USA.
Ruth C CarlosUniversity of Michigan School of Medicine, Ann Arbor, USA.
Kathryn E WeaverWake Forest Baptist Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Funding

ECOG-ACRIN NCORP Research Base - TMISTUG1CA189828 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$199.7M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
Wake Forest NCORP Research BaseUG1CA189824 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Emily Van Meter Dressler, GLENN J LESSER · 2014 to 2026
$57.9M
Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Diane E Mahoney · 2019 to 2026
$21.5M
NCI NIH HHS UG1 CA189824NCI NIH HHS UG1 CA189828NCI NIH HHS UG1 CA189961NCI NIH HHS UG1 CA189974NIGMS NIH HHS P20 GM130423
6 · The paper itself

Abstract

Purpose: Urological cancer clinical trials face accrual challenges, which may stem from structural barriers within cancer programs. We sought to describe the extent to which urology cancer care providers are available within community cancer research programs and explore the role of oncology practice group ownership in their access to urology practices to participate in research. Materials and methods: We conducted secondary analysis of organizational survey data collected in 2017 among National Cancer Institute Community Oncology Research Program practice groups. We used logistic regression to assess the association of self-reported access to urologists to participate in research and oncology practice group ownership type: independent, payor-provider, health-system, or public ownership. Results: Of the 209 community oncology practice groups in the analysis sample, 133 (63.6%) had access to urologists for research participation. Ownership was not statistically significantly associated with access to urology practices after controlling for other covariates (p = 0.4). Instead, having a hospital outpatient clinic (p = 0.008) and identifying as a safety-net hospital (p = 0.035) were both positively significantly associated with access to urologists to participate in research. Conclusions: Two-thirds of community cancer research groups have access to urology. Oncology ownership status was not associated with access to urologists for research. Research groups may need support to increase their capacity to engage non-oncology cancer care providers in research.

Indexed as

CancerClinical trialsDelivery of health careImplementation sciencePatient selection

Identifiers

PMID36033360
PMCPMC9403500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.